Literature DB >> 26597964

Pathogenesis and Therapeutic Strategies in Alzheimer's Disease: From Brain to Periphery.

Jin-Tai Yu1, Can Zhang2.   

Abstract

Alzheimer's disease (AD) is an irreversible, progressive neurodegenerative disorder. At present, there are no effective disease-modifying therapies, and the cause of the disease remains unclear. Previously, almost all researchers focus on the brain for exploring the pathogenesis and therapeutic strategies in AD. A recent study by Xiang et al. (Acta Neuropathol 130:487-499, 2015) reported the significance of the physiological capacity of peripheral tissues and organs in clearing brain-derived amyloid-beta (Aβ), which opens a novel avenue to understand the AD pathogenesis and develop therapies for AD.

Entities:  

Keywords:  Alzheimer’s disease; Amyloid-beta; Pathogenesis; Periphery; Therapy

Mesh：

Substances：

Year:  2015        PMID： 26597964     DOI： 10.1007/s12640-015-9576-2

Source DB:  PubMed          Journal:  Neurotox Res        ISSN： 1029-8428            Impact factor:   3.911


  21 in total

1.  Withania somnifera reverses Alzheimer's disease pathology by enhancing low-density lipoprotein receptor-related protein in liver.

Authors:  Neha Sehgal; Alok Gupta; Rupanagudi Khader Valli; Shanker Datt Joshi; Jessica T Mills; Edith Hamel; Pankaj Khanna; Subhash Chand Jain; Suman S Thakur; Vijayalakshmi Ravindranath
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-30       Impact factor: 11.205

Review 2.  Clearance of amyloid-beta in Alzheimer's disease: progress, problems and perspectives.

Authors:  Yan-Jiang Wang; Hua-Dong Zhou; Xin-Fu Zhou
Journal:  Drug Discov Today       Date:  2006-09-07       Impact factor: 7.851

Review 3.  Clearance mechanisms of Alzheimer's amyloid-beta peptide: implications for therapeutic design and diagnostic tests.

Authors:  K A Bates; G Verdile; Q-X Li; D Ames; P Hudson; C L Masters; R N Martins
Journal:  Mol Psychiatry       Date:  2008-09-16       Impact factor: 15.992

Review 4.  Clearance systems in the brain-implications for Alzheimer disease.

Authors:  Jenna M Tarasoff-Conway; Roxana O Carare; Ricardo S Osorio; Lidia Glodzik; Tracy Butler; Els Fieremans; Leon Axel; Henry Rusinek; Charles Nicholson; Berislav V Zlokovic; Blas Frangione; Kaj Blennow; Joël Ménard; Henrik Zetterberg; Thomas Wisniewski; Mony J de Leon
Journal:  Nat Rev Neurol       Date:  2015-07-21       Impact factor: 42.937

Review 5.  The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics.

Authors:  John Hardy; Dennis J Selkoe
Journal:  Science       Date:  2002-07-19       Impact factor: 47.728

6.  Expression of neprilysin in skeletal muscle reduces amyloid burden in a transgenic mouse model of Alzheimer disease.

Authors:  Yinxing Liu; Christa Studzinski; Tina Beckett; Hanjun Guan; Matthew A Hersh; M Paul Murphy; Ronald Klein; Louis B Hersh
Journal:  Mol Ther       Date:  2009-05-26       Impact factor: 11.454

Review 7.  Clearance of amyloid-beta in Alzheimer's disease: shifting the action site from center to periphery.

Authors:  Yu-Hui Liu; Ye-Ran Wang; Yang Xiang; Hua-Dong Zhou; Brian Giunta; Noralyn B Mañucat-Tan; Jun Tan; Xin-Fu Zhou; Yan-Jiang Wang
Journal:  Mol Neurobiol       Date:  2014-04-15       Impact factor: 5.590

8.  Intramuscular delivery of a single chain antibody gene reduces brain Abeta burden in a mouse model of Alzheimer's disease.

Authors:  Yan-Jiang Wang; Anthony Pollard; Jin-Hua Zhong; Xiao-Yan Dong; Xiao-Bing Wu; Hua-Dong Zhou; Xin-Fu Zhou
Journal:  Neurobiol Aging       Date:  2007-08-07       Impact factor: 4.673

9.  Growth differentiation factor 11 is a circulating factor that reverses age-related cardiac hypertrophy.

Authors:  Francesco S Loffredo; Matthew L Steinhauser; Steven M Jay; Joseph Gannon; James R Pancoast; Pratyusha Yalamanchi; Manisha Sinha; Claudia Dall'Osso; Danika Khong; Jennifer L Shadrach; Christine M Miller; Britta S Singer; Alex Stewart; Nikolaos Psychogios; Robert E Gerszten; Adam J Hartigan; Mi-Jeong Kim; Thomas Serwold; Amy J Wagers; Richard T Lee
Journal:  Cell       Date:  2013-05-09       Impact factor: 41.582

10.  Sustained peripheral depletion of amyloid-β with a novel form of neprilysin does not affect central levels of amyloid-β.

Authors:  Simon J Henderson; Christin Andersson; Rajesh Narwal; Juliette Janson; Tom J Goldschmidt; Paulina Appelkvist; Anna Bogstedt; Ann-Charlott Steffen; Ulrich Haupts; Jan Tebbe; Per Ola Freskgård; Lutz Jermutus; Matthew Burrell; Susan B Fowler; Carl I Webster
Journal:  Brain       Date:  2013-11-20       Impact factor: 13.501
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.